• LAST PRICE
    3.5600
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (1.7143%)
  • Bid / Lots
    3.5400/ 3
  • Ask / Lots
    3.5800/ 5
  • Open / Previous Close
    3.4300 / 3.5000
  • Day Range
    Low 3.4200
    High 3.5800
  • 52 Week Range
    Low 1.0800
    High 6.1400
  • Volume
    46,951
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.5
TimeVolumeGTHX
09:32 ET122083.46
09:34 ET78023.51
09:36 ET24063.54
09:38 ET9223.52
09:39 ET7263.5396
09:43 ET42983.55
09:45 ET3003.565
09:48 ET1003.57
09:50 ET17503.56
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGTHX
G1 Therapeutics Inc
183.0M
-5.8x
---
United StatesCDXC
Chromadex Corp
231.9M
-63.6x
---
United StatesALIM
Alimera Sciences Inc
292.3M
-3.6x
---
United StatesNKTR
Nektar Therapeutics
269.9M
-1.6x
---
United StatesPSNL
Personalis Inc
104.4M
-1.1x
---
United StatesFBIO
Fortress Biotech Inc
45.6M
-0.3x
---
As of 2024-07-17

Company Information

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Contact Information

Headquarters
700 Park Offices Drive, Suite 200RESEARCH TRIANGLE PARK, NC, United States 27709
Phone
919-213-9835
Fax
919-741-5830

Executives

Independent Chairman of the Board
Garry Nicholson
President, Chief Executive Officer, Director
John Bailey
Chief Financial Officer
John Umstead V
Chief Operating Officer
Terry Murdock
Chief Legal and People Officer
Monica Thomas

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$183.0M
Revenue (TTM)
$84.0M
Shares Outstanding
52.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.62
EPS
$-0.61
Book Value
$0.68
P/E Ratio
-5.8x
Price/Sales (TTM)
2.2
Price/Cash Flow (TTM)
---
Operating Margin
-27.16%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.